{"filing":{"accession_number":"0001193125-26-276694","cik":"0000886163","ticker":"LGNYZ","company_name":"LIGAND PHARMACEUTICALS INC","form":"8-K","filing_date":"2026-06-22","report_date":null,"primary_document":"d41408d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/886163/000119312526276694/d41408d8k.htm"},"events":[{"id":12575,"run_id":11154,"accession_number":"0001193125-26-276694","anchor_item_number":"1.01","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.9,"summary":"Ligand entered into a Fourth Amendment to its Credit Agreement on June 22, 2026, to permit the issuance of $550 million of convertible senior notes due 2031 in a private placement to qualified institutional buyers, with an additional $82.5 million option. The amendment accommodates this material debt issuance and affects the company's capital structure.","company_name":"LIGAND PHARMACEUTICALS INC","ticker":"LGNYZ","filing_date":"2026-06-22","form":"8-K","submitted_at":null,"items":[{"id":9463,"accession_number":"0001193125-26-276694","item_number":"1.01","item_title":null,"event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Ligand entered into a Fourth Amendment to its Credit Agreement on June 22, 2026, to permit the issuance of $550 million of convertible senior notes due 2031 in a private placement. The filing discloses the creation of a new direct financial obligation (convertible debt) and amendment of an existing credit facility to accommodate this offering. This is a material debt issuance that creates substantial new financial obligations and affects the company's capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-22T11:13:10.212379+00:00","company_name":"","ticker":null,"filing_date":""},{"id":9464,"accession_number":"0001193125-26-276694","item_number":"8.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"Ligand announced a proposed private placement of $550 million in convertible senior notes due 2031 to qualified institutional buyers under Rule 144A, with an additional $82.5 million option. While this is technically a debt issuance, the filing emphasizes the convertible nature of the notes and explicitly discusses potential dilution to common stock upon conversion, hedge transactions, warrant issuances, and concurrent share repurchases intended to \"offset potential dilution.\" The core material event centers on the dilutive equity component and capital raise structure rather than the debt obligation itself, making dilutive_issuance the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-22T11:13:10.212379+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":9463,"accession_number":"0001193125-26-276694","item_number":"1.01","item_title":null,"event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Ligand entered into a Fourth Amendment to its Credit Agreement on June 22, 2026, to permit the issuance of $550 million of convertible senior notes due 2031 in a private placement. The filing discloses the creation of a new direct financial obligation (convertible debt) and amendment of an existing credit facility to accommodate this offering. This is a material debt issuance that creates substantial new financial obligations and affects the company's capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-22T11:13:10.212379+00:00","company_name":"LIGAND PHARMACEUTICALS INC","ticker":"LGNYZ","filing_date":"2026-06-22"},{"id":9464,"accession_number":"0001193125-26-276694","item_number":"8.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"Ligand announced a proposed private placement of $550 million in convertible senior notes due 2031 to qualified institutional buyers under Rule 144A, with an additional $82.5 million option. While this is technically a debt issuance, the filing emphasizes the convertible nature of the notes and explicitly discusses potential dilution to common stock upon conversion, hedge transactions, warrant issuances, and concurrent share repurchases intended to \"offset potential dilution.\" The core material event centers on the dilutive equity component and capital raise structure rather than the debt obligation itself, making dilutive_issuance the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-22T11:13:10.212379+00:00","company_name":"LIGAND PHARMACEUTICALS INC","ticker":"LGNYZ","filing_date":"2026-06-22"}]}